Dr. Julie Park is a principal investigator at Seattle Children’s Research Institute. She is committed to researching novel therapies for the treatment of high-risk neuroblastoma, a rare but aggressive form of pediatric cancer. She collaborates with Dr. Jensen to develop immunotherapy approaches for neuroblastoma. Dr. Park is now leading a phase 1 clinical trial testing T-cell therapy in children and teens with neuroblastoma that does not respond well to early treatment or reappears post-treatment.
Dr. Park’s work extends far past her research. She is also an attending physician at Seattle Children’s Hospital, professor in pediatrics at the University of Washington School of Medicine and associate in the Clinical Research Division at Fred Hutchinson Cancer Research Center. She is the director of the pediatric hematology-oncology fellowship at the University of Washington. Furthermore, Park is an active member of the Children’s Oncology Group Consortium and as chair of its Neuroblastoma Scientific Committee.